ABSTRACT. To study the pulmonary vasodilator selectivity of low levels of inhaled nitric oxide (NO) in a model of neonatal pulmonary hypertension, we sequentially exposed anesthetized, spontaneously breathing neonatal pigs to each of four different inspired gas mixtures: room air, room air with 25 parts per million NO, hypoxia (14% 0 2 in N2), and hypoxia with 25 parts per million NO. The room air, room air with NO, hypoxia, and hypoxia with NO exposures were of 15-min duration. The following measurements were made: mean systemic arterial, mean pulmonary arterial, and wedge pressures; thermodilution cardiac output; esophageal pressure; tracheal flow; and arterial Po2, Pc02, pH, hemoglobin, and methemoglobin. Inhalation of NO decreased pulmonary arterial pressure in both room air and hypoxia conditions (mean pulmonary arterial pressure 16 f 1 torr room air, 13 f 1 torr room air with NO, p < 0.005; and mean pulmonary arterial pressure 21 f 2 torr hypoxia, 14 f 1 torr hypoxia with NO, p < 0.005).NO had no significant effect on systemic arterial pressure, cardiac output, dynamic lung compliance, pulmonary resistance, or the measured blood variables during either control or hypoxic conditions. The results indicate that inhaled NO was a selective pulmonary vasodilator that could effectively reverse acute hypoxic pulmonary vasoconstriction. The normoxic vasodilation produced by NO inhalation also indicates the existence of basal vasomotor tone in the anesthetized, spontaneously breathing neonatal pig. The short-term exposures used produced no detectable manifestations of toxic side effects. (Pediatr Res 35: 20-24,1994) Abbreviations NO, nitric oxide PVR, pulmonary vascular resistance PPHN, persistent pulmonary hypertension of the newborn Neonatal pulmonary diseases, such as surfactant deficiency, PPHN, and bronchopulmonary dysplasia, often present with pulmonary hypertension and remain an important cause of morbidity and mortality in infants admitted to neonatal intensive care unit. No uniformly efficacious therapy exists for pulmonary hypertension despite many trials of various vasodilators, including tolazoline; chlorpromazine; nifedipine; verapamil; sodium nitroprusside; amrinone; fentanyl; sodium bicarbonate; neuromuscular blockers; and the prostaglandins I*, El, and D2 (1). An efficacious therapy would be one that resulted in a sustained decrease in pulmonary artery pressure with no change in systemic blood pressure and no change or an increase in cardiac output. Many of the vasodilators that have been used in adults with primary pulmonary hypertension were developed for the treatment of systemic hypertension, and none has proved to be a sufficiently selective pulmonary vasodilator (2). In fact, the dose of the vasodilator is usually titrated until a predetermined fall in systemic blood pressure occurs (1, 2). The search for a selective pulmonary vasodilator has recently centered on the endothelial cell. NO has been shown to have an important role in the vasodilator response to a wide variety of agents (3-3, wh...